Wednesday, May 22, 2019So, viagra effects women it is better to take a pill an hour ago, before the successful copulation. Healthy blood purchase generic viagra vessels able to bring more children into the world. They go to promote the medicine to get combat with erectile dysfunction problem. tadalafil cialis generika Like in human beings, excess salt frequently leads to dehydration, kidney dysfunction, thirst and loss of viagra 100 mg http://deeprootsmag.org/2012/09/07/for-that-man-in-the-booth-the-one-with-a-woman-on-each-arm/ life.
CURE Pharmaceutical, an innovative drug delivery and development company, announced the issuance of U.S. Patent No. 10,307,397, which covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. The cannabinoids include cannabidiol (CBD) and tetrahydrocannabinol (THC).
Advances in drug delivery are critical to improving cannabis-based products,” said Rob Davidson, CEO of CURE Pharmaceutical. “This patent secures a critical advantage – the ability to deliver high loads of cannabinoid active molecules with an oral thin film for optimal efficacy and dosing frequency.”
A higher load in oral thin film means 30 percent or more of the cannabinoid molecule is integrated. So, for example, 30mg of cannabidiol (CBD) for a 100mg film. This is meaningful for CBD, as higher doses are often desirable for optimal effect on the endocannabinoid system.
CURE has vertical research and manufacturing operations registered with the DEA to develop and manufacture cannabis-derived and synthetic cannabidiol-based products using its CUREfilm™ technology at its facility in Oxnard, Calif. With CUREfilm, the delivery of cannabinoids is easier and more effective as it offers increased bioavailability, ease and precision of dosing and greater palatability.
Source: Company Press Release